Details
Question
- What is the clinical effectiveness of dabrafenib and trametinib for patients with BRAF mutation positive metastatic melanoma with active or symptomatic brain metastasis?
- What is the clinical effectiveness of cobimetinib and vemurafenib for patients with BRAF mutation positive metastatic melanoma with active or symptomatic brain metastasis?
Key Message
Data from a non-randomized, no control, open-label phase 2 study suggested that the clinical benefit and tolerability of dabrafenib plus trametinib, as measured by intracranial response and adverse event rate, were found in patients with melanoma and active brain metastasis with BRAF V600E mutation after a median 8.5 months follow-up.